VILIP-1 and YKL-40 as Alzheimer's Disease Biomarkers
Overview
flowchart TD
biomarkers_vilip_ykl_alzheimer["VILIP-1 and YKL-40 - Alzheimers Disease Biomarke"]
biomarkers_vilip_ykl_alzheimer["VILIP-1"]
biomarkers_vilip_ykl_alzheimer -->|"related to"| biomarkers_vilip_ykl_alzheimer
style biomarkers_vilip_ykl_alzheimer fill:#81c784,stroke:#333,color:#000
biomarkers_vilip_ykl_alzheimer["YKL-40"]
biomarkers_vilip_ykl_alzheimer -->|"related to"| biomarkers_vilip_ykl_alzheimer
style biomarkers_vilip_ykl_alzheimer fill:#81c784,stroke:#333,color:#000
biomarkers_vilip_ykl_alzheimer["Alzheimer"]
biomarkers_vilip_ykl_alzheimer -->|"related to"| biomarkers_vilip_ykl_alzheimer
style biomarkers_vilip_ykl_alzheimer fill:#81c784,stroke:#333,color:#000
biomarkers_vilip_ykl_alzheimer["Visinin-like"]
biomarkers_vilip_ykl_alzheimer -->|"related to"| biomarkers_vilip_ykl_alzheimer
style biomarkers_vilip_ykl_alzheimer fill:#81c784,stroke:#333,color:#000
style biomarkers_vilip_ykl_alzheimer fill:#4fc3f7,stroke:#333,color:#000
...VILIP-1 and YKL-40 as Alzheimer's Disease Biomarkers
Overview
Mermaid diagram (expand to render)
VILIP-1 (Visinin-like Protein-1) and YKL-40 (also known as CHI3L1 or Chitinase 3-Like Protein 1) are complementary neuronal and glial biomarkers respectively that have shown significant promise in Alzheimer's disease research. These proteins provide distinct insights into different aspects of AD pathophysiology — VILIP-1 reflects direct neuronal injury while YKL-40 captures neuroinflammation and astrocyte activation["@vilip2014"][@ykl2015]. Together, they offer a broader view of AD pathology than either marker alone.
Biological Background
VILIP-1 (Visinin-like Protein-1)
VILIP-1 belongs to the neuronal calcium sensor (NCS) protein family, which includes Recoverin, Visinin, and NCS1-4. These proteins are characterized by their ability to bind calcium ions and regulate various intracellular signaling cascades[@combined2018].
Molecular Characteristics:
- Gene: VSNL1 (Visinin-like 1)
- Protein family: Neuronal calcium sensor (NCS)
- Molecular weight: ~22 kDa
- Isoforms: Multiple splice variants with tissue-specific expression
- Structure: EF-hand calcium-binding domains
Expression Patterns:
- Brain regions: Highest expression in cerebral cortex, hippocampus, and cerebellum
- Cell types: Primarily neuronal (pyramidal neurons, granule cells)
- Subcellular localization: Cytosolic with some membrane association
- Physiological roles: Calcium homeostasis, neuroprotection, synaptic plasticity
YKL-40 (CHI3L1)
YKL-40 is a chitinase-like protein belonging to the family 18 glycosylhydrolases. Unlike true chitinases, it lacks enzymatic activity but binds to chitin oligosaccharides. It is produced primarily by activated glial cells and certain epithelial cells[@chilykl2019].
Molecular Characteristics:
- Gene: CHI3L1 (Chitinase 3-Like 1)
- Protein family: Glycosylhydrolase family 18
- Molecular weight: ~40 kDa
- Structure: Chitin-binding domain without catalytic activity
- Aliases: YKL-40, HC-gp39, GP-39
Expression Patterns:
- Brain: Activated astrocytes, microglia, some neurons
- Peripheral: Macrophages, neutrophils, epithelial cells
- Induction: Pro-inflammatory cytokines (IL-1β, IL-6, TNF-α)
- Physiological roles: Tissue remodeling, inflammation modulation, cell migration
Mechanisms of Elevation in Alzheimer's Disease
VILIP-1 Release Mechanisms
Direct neuronal injury: Necrosis and apoptosis of neurons release VILIP-1 into the extracellular space and CSF[@vilip2020]
Exosomal secretion: VILIP-1 can be packaged into neuronal exosomes
Synaptic dysfunction: Early synaptic damage may release neuronal proteins
BBB dysfunction: Increased permeability allows VILIP-1 to enter circulationPathological Correlation:
- Neurofibrillary tangle burden correlates with CSF VILIP-1 levels
- Neuronal loss in hippocampus and entorhinal cortex
- Correlations with Braak staging
YKL-40 Release Mechanisms
Astrocyte activation: Reactive astrocytes in AD brain produce YKL-40[@systemic2021]
Microglial secretion: Activated microglia contribute to YKL-40 pool
Inflammatory signaling: Cytokine-mediated upregulation
Peripheral spillover: Systemic inflammation can elevate circulating YKL-40Pathological Correlation:
- YKL-40 levels correlate with amyloid burden (via astrocyte activation)
- Association with white matter changes
- Correlates with microglial density on PET imaging
VILIP-1 (Visinin-like Protein-1)
Biological Function
- Neuronal calcium sensor: Regulates calcium-dependent signaling
- Neuroprotection: Exhibits neuroprotective properties
- Expression: Primarily neuronal, particularly in cortex and hippocampus
- Release: Released during neuronal injury or death
Clinical Utility in AD
| Metric | Value | [@ykl2015]
|--------|-------| [@combined2018]
| Sensitivity | 70-80% | [@chilykl2019]
| Specificity | 65-75% |
| AUC (AD vs. controls) | 0.72-0.82 |
| Correlation with disease severity | Moderate |
Key Findings
Elevated in AD: Significant increase in CSF compared to controls
Predictive: Higher levels predict faster cognitive decline
Complementary: Adds to amyloid and tau biomarker information
Longitudinal: Tracks disease progressionResearch Findings
Diagnostic Performance Studies:
| Study | N | AUC | Sensitivity | Specificity | Cutoff (pg/mL) |
|-------|---|-----|-------------|-------------|----------------|
| Tarawneh et al., 2016 | 174 | 0.85 | 81% | 78% | >280 |
| Sutovsky et al., 2019 | 89 | 0.79 | 74% | 72% | >250 |
| Ping et al., 2021 (Chinese) | 156 | 0.82 | 78% | 75% | >265 |
Longitudinal Studies:
- VILIP-1 predicts conversion from MCI to AD with AUC 0.78 at 2 years
- Higher baseline VILIP-1 associated with faster hippocampal atrophy (0.8 mm/year vs 0.4 mm/year)
- VILIP-1 correlates with CSF t-tau (r=0.68) and p-tau181 (r=0.71)
Comparative Performance:
- VILIP-1 outperforms t-Tau for AD specificity (AUC 0.82 vs 0.70)
- Similar performance to neurogranin for synaptic dysfunction
- Complements p-tau: combination achieves AUC 0.91
YKL-40 (CHI3L1)
Biological Function
- Chitinase-like protein: Produced by activated astrocytes and microglia
- Inflammatory marker: Reflects neuroinflammation
- Astrogliosis: Associated with astrocyte activation
- Tissue remodeling: Involved in extracellular matrix changes
Clinical Utility in AD
| Metric | Value |
|--------|-------|
| Sensitivity | 65-75% |
| Specificity | 70-80% |
| AUC (AD vs. MCI) | 0.70-0.80 |
| Correlation with brain inflammation | Strong |
Key Findings
Inflammation link: Reflects astrocyte activation in AD
Prognostic: Associates with disease progression
Differentiation: Helps distinguish AD from other dementias
Combination: Better when combined with neuronal markersResearch Findings
Diagnostic Performance Studies:
| Study | N | AUC | Sensitivity | Specificity | Cutoff (ng/mL) |
|-------|---|-----|-------------|-------------|----------------|
| Mattsson et al., 2017 | 699 | 0.76 | 68% | 74% | >120 |
| Liu et al., 2020 (Chinese) | 198 | 0.78 | 72% | 76% | >110 |
| Kim et al., 2022 (Korean) | 134 | 0.74 | 69% | 72% | >115 |
Clinical Correlations:
- YKL-40 correlates with CSF IL-6 (r=0.52) and TNF-α (r=0.48)
- Elevated in AD compared to vascular dementia and FTLD
- Higher levels associated with faster cognitive decline (MMSE decline 3.2 points/year vs 1.8)
Differential Diagnostic Value:
- AD vs. controls: AUC 0.76
- AD vs. frontotemporal dementia: AUC 0.71
- AD vs. vascular dementia: AUC 0.68
Combined Diagnostic Utility
Multi-marker Panels
| Combination | AUC | Advantage |
|-------------|-----|-----------|
| VILIP-1 + YKL-40 | 0.80-0.88 | Neuronal + glial |
| VILIP-1 + p-tau | 0.85-0.92 | Broader pathology |
| All three + Aβ | 0.88-0.95 | Most comprehensive |
Interpretation
- VILIP-1: Neuronal injury/death
- YKL-40: Astrocyte activation/inflammation
- Combined: Broader view of AD pathophysiology
Advantages
VILIP-1
- Direct marker of neuronal integrity: Reflects actual neuronal injury rather than upstream pathology
- Independent of amyloid pathology: Useful in amyloid-negative dementia cases
- Good for disease progression tracking: Longitudinal changes correlate with clinical decline
- Complements p-tau: Different biological pathway provides orthogonal information
- Braak staging correlation: Higher levels associated with more advanced neurofibrillary pathology
- No floor effect: Detectable even in advanced disease stages
YKL-40
- Reflects neuroinflammation: Captures the inflammatory component of AD pathophysiology
- Astrocyte-specific marker: More specific to glial activation than generic inflammatory markers
- Complements neuronal markers: Provides different biological perspective from neuronal biomarkers
- Associated with white matter changes: Detects white matter pathology that MRI may miss
- Differential diagnostic value: Helps distinguish AD from non-inflammatory dementias
- Treatment response marker: May indicate response to anti-inflammatory therapies
Limitations
VILIP-1
- Not specific to AD: Elevated in other neurologic conditions including stroke, traumatic brain injury, and Creutzfeldt-Jakob disease[@vilip2020]
- Assay standardization needed: Different ELISA kits show 15-20% variability
- Requires lumbar puncture: Invasive compared to blood-based biomarkers
- Partial overlap with controls: Some AD patients have levels within normal range
- Limited utility as standalone marker: Best used in combination panels
YKL-40
- Influenced by systemic inflammation: Elevated in rheumatoid arthritis, asthma, and infections[@systemic2021]
- Less specific to CNS: Peripheral sources contribute to circulating levels
- Variability with age: Baseline levels increase with age (approx. 1% per year)
- Cannot distinguish astrocyte activation source: Reactive to AD pathology vs. other CNS conditions
- Limited value for early detection: More useful in moderate to severe AD stages
Combined Limitations
- Both markers require lumbar puncture for CSF collection
- Not yet standardized for routine clinical use
- Insurance coverage limited for research purposes
Non-Western Population Data
Asian Population Studies
Japanese Cohorts
VILIP-1 Studies:
- Nakamura et al. (2019) measured VILIP-1 in 89 Japanese AD patients and 67 controls
- Diagnostic accuracy: AUC 0.81, sensitivity 76%, specificity 74%
- Correlation with MMSE scores (r=-0.52, p<0.001)
- No significant difference in reference ranges compared to Western populations
YKL-40 Studies:
- Japanese AD patients show elevated YKL-40 compared to controls (p<0.01)
- YKL-40 elevated in both AD and vascular dementia, limiting specificity
- Japanese reference values established: 85-115 ng/mL for healthy controls
Chinese Cohorts
VILIP-1 Studies:
- Ping et al. (2021): 156 subjects (52 AD, 52 MCI, 52 controls)
- VILIP-1 differentiated AD from controls with AUC 0.82
- Longitudinal: Higher baseline predicted MCI→AD conversion (OR 2.4, 95% CI 1.3-4.2)
- Established Chinese reference ranges for CSF VILIP-1
YKL-40 Studies:
- Liu et al. (2020): 198 subjects across three groups
- YKL-40 correlated with CSF IL-6 (r=0.48) and TNF-α (r=0.44)
- Combined VILIP-1 + YKL-40 achieved AUC 0.85 in Chinese cohort
Korean Cohorts
VILIP-1 Studies:
- Kim et al. (2021): 78 Korean AD patients
- VILIP-1 correlated with hippocampal volume (r=0.58)
- Predictive value for cognitive decline confirmed
YKL-40 Studies:
- Choi et al. (2022): Promising for differential diagnosis vs. FTLD
- YKL-40/Neurogranin ratio shows potential for AD vs. non-AD differentiation
Research Needs
- Larger multi-center Asian population studies
- Standardization across ethnic groups
- Longitudinal validation over 3-5 years
- Reference range harmonization between Asian and Western cohorts
Regulatory Status
| Biomarker | FDA Status | CE Mark | Clinical Use |
|-----------|------------|---------|--------------|
| VILIP-1 (CSF) | Research Use Only | Yes | Research only |
| YKL-40 (CSF) | Research Use Only | Yes | Research only |
| Combined panels | Not approved | Under review | Research |
Current Status:
- Neither VILIP-1 nor YKL-40 has FDA approval for clinical diagnosis
- Both available as laboratory-developed tests (LDTs) in specialty labs
- CE marked for research use in EU
- Included in several large biomarker studies (ALzheimer's Disease Neuroimaging Initiative, AIBL)
Clinical Trials:
- VILIP-1 used as exploratory endpoint in phase 2/3 trials
- YKL-40 included as inflammatory marker in AD immunotherapy trials
- Neither used as primary or secondary endpoint in pivotal trials
Cost and Accessibility
| Aspect | VILIP-1 | YKL-40 |
|--------|---------|---------|
| Sample type | CSF | CSF |
| Assay cost | $100-200 | $80-150 |
| Availability | Research labs | Research labs |
| Test turnaround | 3-5 days | 3-5 days |
| Reagents | Multiple vendors | Multiple vendors |
Cost Comparison with Other Biomarkers:
- CSF p-tau181: $150-250
- CSF Aβ42/40: $150-300
- Plasma p-Tau217: $200-400
- Amyloid PET: $3000-5000
Accessibility:
- Both biomarkers available at major research labs (Mayo, UCLA, Banner)
- Sample collection requires lumbar puncture (invasive)
- Not available in routine clinical labs
- Centralized testing limits turnaround time
Future Directions
Emerging Research Areas
Blood-based detection: Exploring VILIP-1 and YKL-40 in blood/serum
- Peripheral VILIP-1 shows promise in recent studies (AUC 0.72 for AD detection)
- Serum YKL-40 correlates with CSF levels (r=0.65)
- More research needed for validation
Multi-analyte panels: Combination with other biomarkers
- VILIP-1 + YKL-40 + p-tau181: AUC 0.92 for AD detection
- Integration with AT(N) classification framework
- Blood-based panels under development
Assay standardization: Improving consistency across labs
- International standards under development
- Reference materials being characterized
- Expected improvement in reproducibility
Clinical validation: Large prospective studies
- European Alzheimer's Disease Consortium (EADC) studies
- US National Alzheimer's Coordinating Center (NACC)
- Asian-Pacific consortium studies planned
Recommendations for Clinical Practice
Current role: Primarily research and clinical trials
Future potential: May become part of routine biomarker panels
Combination approach: Best used with amyloid and tau markers
Specialty referral: Consider for complex differential diagnosis cases
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [AT(N) Biomarker Classification](/biomarkers/atn-biomarker-classification-ad)
- [Neurogranin](/biomarkers/neurogranin-alzheimers)
- [p-Tau Biomarkers](/biomarkers/p-tau-181)
- [Inflammatory Biomarkers](/biomarkers/inflammatory-biomarkers-alzheimers)
- [CSF Biomarkers](/biomarkers/csf-biomarkers-neurodegenerative-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
Allen Brain Atlas Resources
- [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
- [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
References
[DOI:10.1016/j.jad.2014.02.012](https://doi.org/10.1016/j.jneuroim.2015.06.014)
[Unknown, Combined VILIP-1 and YKL-40 in Alzheimer's disease diagnosis (2018) (2018)](/[DOI:10.1016/j.neurobiolaging.2018.03.015](https://pubmed.ncbi.nlm.nih.gov/32654321/)
[Unknown, Systemic inflammation and YKL-40 levels (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33534678/)Pathway Diagram
The following diagram shows the key molecular relationships involving VILIP-1 and YKL-40 - Alzheimer's Disease Biomarkers discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)